<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">ENDO, JUNKI</style></author><author><style face="normal" font="default" size="100%">IIHARA, HIROTOSHI</style></author><author><style face="normal" font="default" size="100%">YAMADA, MAYA</style></author><author><style face="normal" font="default" size="100%">YANASE, KOUMEI</style></author><author><style face="normal" font="default" size="100%">KAMIYA, FUMIHIKO</style></author><author><style face="normal" font="default" size="100%">ITO, FUMITAKA</style></author><author><style face="normal" font="default" size="100%">FUNAGUCHI, NORIHIKO</style></author><author><style face="normal" font="default" size="100%">OHNO, YASUSHI</style></author><author><style face="normal" font="default" size="100%">MINATOGUCHI, SHINYA</style></author><author><style face="normal" font="default" size="100%">ITOH, YOSHINORI</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">A Randomized Controlled Non-inferiority Study Comparing the Antiemetic Effect between Intravenous Granisetron and Oral Azasetron Based on Estimated 5-HT&lt;sub&gt;3&lt;/sub&gt; Receptor Occupancy</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-09-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">3939-3947</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><issue><style face="normal" font="default" size="100%">9</style></issue><abstract><style  face="normal" font="default" size="100%">Background: The acute antiemetic effect was compared between oral azasetron and intravenous granisetron based on the 5-hydroxytryptamine3 (5-HT3) receptor occupancy theory. Patients and Methods: Receptor occupancy was estimated from reported data on plasma concentrations and affinity constants to 5-HT3 receptor. A randomized non-inferiority study comparing acute antiemetic effects between oral azasetron and intravenous granisetron was performed in 105 patients receiving the first course of carboplatin-based chemotherapy for lung cancer. Results: Azasetron exhibited the highest 5-HT3 receptor occupancy among various first-generation 5-HT3 antagonists. The complete response to oral azasetron was shown to be non-inferior to that of intravenous granisetron, in which the risk difference was 0.0004 (95% confidence interval: −0.0519-0.0527). The lower limit of the confidence intervals did not exceed the negative non-inferiority margin (−0.1). The complete response during the overall period was not different (68% versus 67%). Conclusion: Oral azasetron was found to be non-inferior to intravenous granisetron in the acute antiemetic effect against moderately emetogenic chemotherapy.</style></abstract></record></records></xml>